



EBEC EXPO2024

Proskauer's Perspective
on Employee Benefits,
Executive Compensation
and ERISA Litigation

Proskauer»



EBEC
EXPO2024

Health Plans in the Hot Seat: Practical Advice on Navigating New Legislation, Regulation and Litigation

Katrina E. McCann
Jennifer Rigterink

May 2, 2024

Proskauer»

Meet Your Presenters



Katrina E. McCann

Special Counsel
New York
+1.212.969.3639
kmccann@proskauer.com



Jennifer Rigterink

Special Counsel
New Orleans
+1.504.310.2030
jrigterink@proskauer.com

Health Plans in the *Hot* Seat

- Plans wrestling with impact of legislation passed in the last few years
 - Transparency requirements and disclosures
 - No Surprises Act (and continued litigation regarding implementation)
- Increased regulatory activity
 - Mental health parity proposed regulations
 - Implementation of final rules on transparency
 - Agency focus on copayment assistance and copayment maximizer programs
- New litigation brought against plans and providers
 - Focus on ERISA fiduciary responsibility, service provider compensation

Overview of Topics

- Mental health parity
 - Proposed regulations
- Implementation of surprise billing rules
 - Overview of rules
 - Rocky implementation process
 - Initial impressions and suggestions
- Overview of trending health plan litigation



Mental Health Parity – Proposed Regulations


May 2, 2024

Overview of MHPAEA Key Concepts

Requirement	Key Concepts
Annual or lifetime limits	<ul style="list-style-type: none"> • Need to apply the same (or higher) annual or lifetime dollar limit on MH/SUD benefits as medical benefits
Financial requirements and quantitative treatment limitations (QTLs)	<ul style="list-style-type: none"> • Cannot apply more restrictive quantitative treatment limits or financial requirements (QTLs) to MH/SUD benefits than to medical/surgical benefits • Mathematical test: <ul style="list-style-type: none"> • If QTL <u>does not</u> apply to “substantially all” medical/surgical benefits in a classification, cannot be applied to MH/SUD benefits in that classification • If QTL <u>does</u> apply to “substantially all” medical/surgical benefits in a classification, may be applied to MH/SUD benefits in that classification, but only if the restriction is not more restrictive than the “predominant level” applied to medical/surgical benefits
Nonquantitative treatment limitations (NQTLs) <i>pending proposed regs</i>	<ul style="list-style-type: none"> • Cannot impose nonquantitative treatment limitations (NQTLs) on MH/SUD benefits unless the processes, strategies, evidentiary standards, and other factors used in applying them are comparable to, and applied no less stringently, than the same criteria as applied to medical/surgical benefits

MHPAEA Classifications


- MHPAEA works by comparing the treatment of medical/surgical benefits to MH/SUD benefits within separate classifications:



MHPAEA – Current Rules v. Proposed Rules

2013 Rule and Guidance	Proposed Rules
<p>NQTL assessment is process-oriented</p> <ul style="list-style-type: none"> Looks at whether NQTL is comparable and no more stringent, in writing and in operation, than NQTL applied on medical/surgical side 	<p>New NQTL 3-part test:</p> <ul style="list-style-type: none"> No more restrictive (math) Design and application Data evaluation (material difference=non-compliance; special rule for network composition NQTL)
<p>If plan covers MH/SUD in benefit classification, must cover MH/SUD in all classifications</p>	<p>If plan covers MH/SUD condition in a benefit classification, must cover “meaningful benefits” for that condition in every classification, as compared to medical/surgical</p>
<p>NQTL comparative analysis content (ACA FAQs 45)</p>	<p>NQTL comparative analysis content, description of NQTLs</p> <ul style="list-style-type: none"> More elements Fiduciary certification
<p>If DOL makes final determination of non-compliance, notice to participants and listing in Report to Congress</p>	<p>If DOL makes final determination of non-compliance, notice to participants, listing in Report to Congress <u>and</u> DOL can order plan not to apply NQTL to MH/SUD benefits</p>

NQTL – Proposed Three-Part Test



MHPAEA Data Evaluation - Network Composition for NQTLs

Required data collection

- Out-of-network utilization
- Percentage of in-network providers actively submitting claims
- Time and distance standards
- Reimbursement rates

Potential safe harbor *if* meet or exceed specific data-based standards

- Enforcement relief for two calendar years

MHPAEA Comparative Analysis Content Requirements

- Description of NQTL
- Identification and definition of the factors used to design or apply the NQTL
- Description of how factors are used in the design and application of the NQTL
- Demonstration of comparability and stringency as written
- Demonstration of comparability and stringency in operation
- Findings and conclusions
- For ERISA plans: **Certification by named fiduciaries**



Implementation of Surprise Billing Requirements

May 2, 2024

Surprise Billing Rules: Refresher

- The “No Surprises Act” was part of the Consol. Appropriations Act of 2021
 - DOL, Treasury, HHS and the Office of Personnel Management
- Designed to reduce “surprise” medical bills and balance billing
 - Prohibits balance billing of participants in specified circumstances
 - Adds notice requirements for plans, insurers, providers & facilities
 - Sets coverage, payment and dispute resolution requirements for plans
- Covers group health plans, health insurers, facilities & providers, and air ambulances
 - Includes grandfathered plans, HDHPs
 - Does not include HRAs, excepted benefits, retiree plans, ground ambulances, etc.

Surprise Billing Rules: Impact on Participants

- **Emergency Benefits:** If covered, OON emergency services must be covered without pre-authorization and as if in-network
- **Non-Emergency Benefits:** If covered, services by OON providers at in-network facility covered as if in-network, absent notice & consent
- **Air Ambulance:** If covered, OON air ambulances covered as if in-network
- **Cost Sharing:**
 - Same as in-network (as if total charged is the “recognized amount”)
 - Counts toward:
 - In-network deductibles
 - Out-of-pocket maximums
- **Balance Billing:** Prohibited

Surprise Billing Rules: Impact on Plans

- Initial updates to plan documents, SPDs, SBSs as necessary to reflect rules
- Participant cost sharing based on “Qualifying Payment Amount” (QPA)
 - Unless determined based on All-Payer Model Agreement under SSA 1115A or state law
 - Not based on whatever the plan ends up paying to the provider
- Determining QPA
 - Median contracted rate of the plan or issuer as of 1/31/19, as indexed
 - Must be for same market, same/similar items or services and facility type, same geographic region
 - Specific rules for determining QPA when there is insufficient information, non-fee-for-service arrangements, unit-based services, anesthesia, air ambulances


Surprise Billing Rules: Impact on Plans (Cont.)

- Must be able to timely identify and process No Surprises claims
 - Initial payment (or denial) due 30 calendar days after transmission of the bill
 - EOBs must contain required information, including QPA for each item or service, apply appropriate cost sharing, notify provider of 30-day negotiation period and IDR process
- Must establish initial payment amount
 - If not determined by All-Payer Model Agreement under SSA 1115A or state law, then payment amount must be agreed upon or determined through IDR
 - Plans have taken various approaches for initial payment amount
 - QPA
 - X% of Medicare
 - Other

Surprise Billing Rules: Impact on Plans (Cont.)

- Must sort out negotiation and dispute resolution processes
 - Work with TPAs or other entities to allocate responsibility and update applicable contracts
 - 30 business days to invoke negotiation period if unsatisfied with initial payment
 - 30-business day negotiation period for agree upon a payment amount
 - 4 business days after negotiation period for either party (generally provider) to negotiate the independent dispute resolution (“IDR”) process (may continue negotiating)
 - Deadlines for selecting IDR entity
 - 10 business days for each party to submit proposed payment amount
 - 30 calendar days to make payment after IDR entity makes a determination
- Increased costs based on QPA payments and results of IDR

Surprise Billing Rules: Federal IDR Timeline




Surprise Billing Rules: A Rocky IDR Rollout

- “Baseball-style” arbitration, so the stakes are high
 - IDR entity selects one of the submitted amounts
 - Limited opportunity for explanation or responses
- Moving target on provider payment amounts
 - Court invalidated the regulatory presumption that QPA would be sufficient absent credible evidence clearly indicating it is materially different from what would be appropriate
 - Held that the presumption conflicted with the text of the No Surprises Act and HHS improperly bypassed certain regulatory processes
 - Now: IDR entities are to give equal weight to all required factors in determining appropriate amount. In addition to QPA, these include:
 - Training and experience level
 - Quality and outcomes measurement
 - Market share held by provider/facility or plan/issuer in the geographic region
 - Patient acuity and complexity of service
 - Good faith efforts (or lack of effort) to join the network and previously contracted rates

Surprise Billing Rules: A Rocky IDR Rollout (Cont.)

- Federal IDR process via an online portal
 - Limited opportunity for feedback
 - Limited ability to correct errors
 - Difficult to halt once started
 - No fee or recourse if submission is ineligible
 - Issues with incomplete information
 - Plan contact information
 - Amounts and deadlines in awards
- System overwhelmed – many more IDR submissions than anticipated (GAO)
 - IDR entities are dealing with backlog, handling high volumes (not necessarily carefully)
 - 490,000 disputes submitted from April 2022 through June 2023, with submission rates increasing
 - Had anticipated 22,000 for 2022
 - 61% of those cases were unresolved in June 2023 (reportedly due to complexity in evaluating eligibility)

INITIAL ROLLOUT



Source: Departments of Health and Human Services, Labor, and Treasury; Centers for Medicare & Medicaid Services. | GAO-24-106335

Surprise Billing Rules: Initial Impressions on Implementation

- Extensive litigation around QPA calculation and impact
 - *Texas Medical Association et al. v. HHS et al* (“TMA III”)
 - Providers successfully challenged 2021 regulations outlining QPA calculation methodology
 - Can no longer use TPA’s client base; calculation has to be plan-by-plan
 - Overhaul of QPA calculation processes needed, recognized by agencies in FAQ, enforcement discretion for items and services before May 1, 2024
 - Decision appealed to the Fifth Circuit
 - TMA III and TMA IV court orders temporarily halted new IDRs from Aug – Dec ’23
 - TMA IV vacated increase in administration fee (from \$50 to \$350)
- Providers are winning, and winning big
 - Agencies released data indicating that providers won 77% of disputes in 2023 Q1 & Q2
 - Awards have averaged 322% of the QPA
 - Anecdotal accounts that IDR payments are or close to largest payments made by plans

Surprise Billing Rules: Initial Impressions on Implementation (Cont.)

- QPA does not appear to be a safe bet
 - Providers are supporting their proposals with information based on the other factors
 - Plans have limited opportunity to contest providers' rationale
 - TPAs typically are not submitting any additional information
- TPA issues
 - Have tended to minimize their role, even when they have agreed to manage the process
 - Communication issues (plans getting late notifications, lack of clarity on results and payment deadlines, difficulty getting access to IDR reports)
- Lack of consistency in determinations, lack of rationale
- Insurance companies reporting similar IDR experience for insured products
 - Potential premium increases?

Surprise Billing Rules: Potential Considerations

- Evaluate TPA agreements and performance
 - Do the agreements clearly delineate responsibilities and service standards?
 - Is the TPA living up to these standards and providing appropriate reporting?
 - If the process isn't working, what changes can be made?
- Re-thinking negotiations and payment proposals
 - What are your initial payment amounts?
 - Would an increase change provider behavior (maybe not, given IDR outcomes)?
 - What are you offering (or have authorized TPA to offer) during negotiations?
 - What amounts are being submitted to IDR entity?
 - For example, some only authorized up to QPA (often not enough)
 - What will TPA administer?
 - Is there any additional information that can/should be submitted as part of the process?



Health Plan Litigation

May 2, 2024

Currently Trending . . . Health Plan Litigation

Category	Examples
Mental health parity	<ul style="list-style-type: none">• Coverage of residential treatment• Coverage of wilderness therapy
Out-of-network, overlay arrangements	<ul style="list-style-type: none">• In-network v. OON participant cost-sharing for repriced claims• Steerage towards OON providers
ACA Section 1557	<ul style="list-style-type: none">• Coverage of gender affirming care (<i>also impacts mental health parity</i>)• Coverage of fertility services
ERISA fiduciary	<ul style="list-style-type: none">• Retention of prescription drug rebates• Impact of service provider fees on participant cost-sharing• Imprudent structure and compensation paid to pharmacy benefit manager• Imprudent PBM compensation (pass-through v. spread pricing)

Observations and Practical Steps

Category	Key Details
Health and welfare plan fiduciary committee	<ul style="list-style-type: none">• Formalization• Process• Records
Prudent selection and monitoring process	<ul style="list-style-type: none">• Interaction with transparency limits• Access to claims information• Claims audits (impact of AI and other tools)• Think ahead — include in ASA, amendments
ERISA 408(b)(2) service provider disclosures	<ul style="list-style-type: none">• Consultants, brokers• Other providers (impact on contracting)
Benchmarking of fees, costs, compensation	<ul style="list-style-type: none">• PBM implications• RFP process

Bonus *Hot* Topic: Copayment Assistance

- Impact on out-of-pocket accumulators
 - **2020 final rule:** Plans have discretion to count (or not count) copayment assistance towards plan accumulators for prescription drugs with medically appropriate generic equivalent
 - **2021 final rule:** Plans have discretion to count (or not count) copayment assistance towards accumulators for prescription drugs regardless of availability of medically appropriate generic equivalent
 - ***HIV Institute v. Department of Health and Human Services (D.D.C. 2023)*:** Vacated 2021 final rule, meaning 2020 final rule is now in effect pending future rulemaking
- Impact on high-deductible health plans
 - HDHP required to disregard discounts, manufacturer coupons towards minimum deductible (amounts must be paid by individual)
 - Potential conflict between reinstated 2020 final rule and HDHP requirements

Bonus *Hot* Topic: Copayment Maximizers

- Some maximizer programs keyed to reclassification of certain prescription drugs as non-EHBs
 - Copayment is increased to available assistance (enrolled participants pay \$0 copayment)
 - Continued litigation between drug manufacturers and copayment maximizer programs under ERISA and state law theories
- Starting in 2025:
 - Prescription drugs in excess of state benchmark plan will be classified as EHBs for individual and small group market plans
 - Continued viability of copayment maximizer programs unclear under new rule
- Future rulemaking will extend same policy to large group market and self-insured plans (announced in ACA FAQs 66)

EBEC EXPO2024

Proskauer's Perspective on Employee Benefits, Executive Compensation and ERISA Litigation

Proskauer»

The information provided in this slide presentation is not intended to be, and shall not be construed to be, either the provision of legal advice or an offer to provide legal services, nor does it necessarily reflect the opinions of the firm, our lawyers or our clients. No client-lawyer relationship between you and the firm is or may be created by your access to or use of this presentation or any information contained on them. Rather, the content is intended as a general overview of the subject matter covered. Proskauer Rose LLP (Proskauer) is not obligated to provide updates on the information presented herein. Those viewing this presentation are encouraged to seek direct counsel on legal questions. © Proskauer Rose LLP. All Rights Reserved.